Bright Minds Biosciences Inc.

DRUG

NASDAQHealthcareBiotechnology

Open in GoAI

Regular session

$77.07

−$0.35 · -0.45%

Aug 24, 10:33 AM ET

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

44/100

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

Expensive

Momentum

Neutral

Sentiment

Bullish

Risk resilience

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company’s BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.

Industry: Biotechnology
Sector: Healthcare
Headquarters: US
CEO: Ian McDonald
Listed since: Mar 22, 2021
Employees: 26

Market position

Day range

Current $77.07

$74.44$77.98

52-week range

Current $77.07

$38.00$123.75

Open: $77.05
Previous close: $77.42
Volume: 12.64K; 0.05× average
Average volume: 272.47K; Average daily volume
Market cap: 754.3M USD
Beta: 0.09; Market reference 1
50-day average: $72.3214; +6.57% above average
200-day average: $77.0757; -0.01% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value: 497.97M CAD
P/E (TTM): -37.3×
P/B (TTM): 3.45×
P/S (TTM): 0×
EV / EBITDA: -40.98×
Earnings yield: -2.11%
Free cash flow yield: -1.50%
Dividend yield: 0.00%

Profitability & efficiency

Gross margin: 0.00%
Operating margin: 0.00%
Net margin: 0.00%
Return on equity: -14.91%
Return on assets: -14.49%
Return on invested capital: -16.96%

Financial health

Debt / equity: 0×
Current ratio: 36.1×

Financial statements

Income trends

Operating income

−13.94M CAD-393.76%

Net income

−12.23M CAD-336.46%

Metric (CAD)	FY2025	FY2024	FY2023	FY2022	FY2021
Research and development	11.08M CAD	1.18M CAD	5M CAD	12.18M CAD	6.31M CAD
Selling, general, and administrative	2.57M CAD	1.45M CAD	2.2M CAD	2.55M CAD	2.31M CAD
Operating expenses	13.94M CAD	2.82M CAD	7.39M CAD	14.98M CAD	8.62M CAD
Interest income	1.52M CAD	30.13K CAD	—	—	—
Depreciation and amortization	76.87K CAD	73.36K CAD	72.45K CAD	6.04K CAD	8.62M CAD
Operating income	−13.94M CAD	−2.82M CAD	−7.39M CAD	−14.98M CAD	−8.62M CAD
Net income	−12.23M CAD	−2.8M CAD	−7.37M CAD	−14.96M CAD	−8.65M CAD